FABP5 and hepatocellular carcinoma: Our comprehensive investigations revealed that the combination of FABP5‐targeted nanoparticles with RFA exhibited robust antitumor efficacy against HCC via ferroptosis‐dependent mechanisms, which could be specifically attenuated by Lipro1 intervention.